|DB00112||Bevacizumab||As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.|
|DB00480||Lenalidomide||Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.|
|DB01041||Thalidomide||For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.|
|DB01268||Sunitinib||For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.|
|DB01270||Ranibizumab||For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
|DB02709||Resveratrol||Being investigated for the treatment of Herpes labialis infections (cold sores).|
|DB04866||Halofuginone||For the treatment of scleroderma, cancer, and restenosis.|
|DB05288||Anecortave acetate||Investigated for use/treatment in glaucoma and macular degeneration.|
|DB06423||Endostatin||Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.|
|DB06436||Semaxanib||Investigated for use/treatment in colorectal cancer and lung cancer.|
|DB06461||Squalamine||Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.|
|DB06589||Pazopanib||Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
|DB08910||Pomalidomide||Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.|
|DB11366||Roquinimex||Roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions.
As well, roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia. |
|DB06647||Volociximab||Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.|